Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy

doi:10.3748/wjg.v28.i42.6034

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 28, Issue 42

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4145)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

235

WORD

HTML

2144

Figures (1-1)

204

Tables (1-2)

124

Sum=2745

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

124

Download

355

Sum=479

Publishing Process of This Article

Item

Count

Browse

238

Download

683

Sum=921

Nov 14, 2022 (publication date) through Apr 28, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. Nov 14, 2022; 28(42): 6034-6044
Published online Nov 14, 2022. doi: 10.3748/wjg.v28.i42.6034

Open in New Tab Full Size Figure Download Figure

Figure 1 Vascular endothelial growth factor promotes the formation of an immune suppressive microenvironment. VEGF: Vascular endothelial growth factor; DCs: Dendritic cells; MDSCs: Myeloid-derived suppressor cells; TAMs: Tumor-associated macrophages; Tregs: Regulatory T cells.

Citation: Li SQ, Yang Y, Ye LS. Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy. World J Gastroenterol 2022; 28(42): 6034-6044
URL: https://www.wjgnet.com/1007-9327/full/v28/i42/6034.htm
DOI: https://dx.doi.org/10.3748/wjg.v28.i42.6034